Should I Buy PETS? PETS 2026 Analysis

Should You Buy Petmed Express Inc (PETS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.230

1 Day change

-1.52%

52 Week Range

5.580

Analysis Updated At

2026/01/26

Petmed Express Inc (PETS) is not a good buy for a beginner, long-term investor at the moment. The company's financial performance is deteriorating significantly, and there are no strong positive catalysts or trading signals to justify an immediate investment. The technical indicators and options data do not suggest a favorable entry point either.

Technical Analysis

The MACD is negative and expanding downward (-0.0481), indicating bearish momentum. RSI is neutral at 44.48, showing no clear signal. Moving averages are converging, suggesting indecision in price movement. Key support is at 3.265, and resistance is at 3.487. The stock is trading below the pivot level of 3.376, which is a bearish sign.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

The low Open Interest Put-Call Ratio indicates a bullish sentiment, but the high Option Volume Put-Call Ratio (23.0) suggests significant bearish activity in the short term. Implied volatility is high (117.9), which could indicate uncertainty.

Technical Summary

Sell

Buy

Positive Catalysts

Insider buying has increased by 174.01% in the last month, which could indicate confidence from insiders.

Neutral/Negative Catalysts

No recent news or events driving positive sentiment. Financial performance is significantly deteriorating, with revenue, net income, and EPS all showing sharp declines. Gross margin has also dropped significantly. Additionally, no recent trading activity from Congress or influential figures has been reported.

Financial Performance

In Q2 2026, revenue dropped by -23.57% YoY to $44.36M. Net income declined by -466.29% YoY to -$8.52M. EPS fell by -472.73% YoY to -$0.41. Gross margin decreased by -22.52% YoY to 22.85%. Overall, the company's financials are weak and trending downward.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

Analyst Rating

Wall Street analysts forecast PETS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PETS is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 3.280

Low

Averages

High

Current: 3.280

Low

Averages

High

Morgan Stanley

Erin Wright

Sell

Maintains

$3.5 → $3.2

AI Analysis

2025-04-17

Reason

Morgan Stanley

Erin Wright

Price Target

$3.5 → $3.2

AI Analysis

2025-04-17

Maintains

Sell

Reason

Morgan Stanley lowered the firm's price target on PetMed Express to $3.20 from $3.50 and keeps an Underweight rating on the shares. The pet medication market has become increasingly competitive and 49% of veterinarians in the firm's survey suggest PetMed Express is losing incremental share, the analyst tells investors. The firm is tempering its target on a tougher consumer macro environment and competitive headwinds following its proprietary AlphaWise survey of 75 U.S. companion animal veterinarians.

PETS Should I Buy

PETS Should I Buy

Should You Buy Petmed Express Inc (PETS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch